HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

EDP 420

a bicyclolide with anti-infective activity

Also Known As:

EDP-420; EDP420; EP-013420; S-013420; modithromycin

Networked: 9 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Bridged-Ring Compounds: 1
      - EDP 420: 9
- Lactones: 1549
  - Macrolides: 4391
    - EDP 420: 9
  - Polyketides: 231
    - Macrolides: 4391
      - EDP 420: 9
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Polyketides: 231
    - Macrolides: 4391
      - EDP 420: 9
- Bridged-Ring Compounds: 1
  - EDP 420: 9

Experts

1.	Wang, Guoqiang: 4 articles (06/2014 - 05/2007)
2.	Phan, Ly T: 2 articles (06/2014 - 03/2008)
3.	Ishii, Yoshikazu: 2 articles (07/2011 - 04/2011)
4.	Kimura, Soichiro: 2 articles (07/2011 - 04/2011)
5.	Sato, Takafumi: 2 articles (07/2011 - 04/2011)
6.	Tateda, Kazuhiro: 2 articles (07/2011 - 04/2011)
7.	Yamaguchi, Keizo: 2 articles (07/2011 - 04/2011)
8.	Jiang, Li-Juan: 2 articles (08/2009 - 05/2009)
9.	Or, Yat Sun: 2 articles (08/2009 - 05/2009)
10.	Bermudez, Luiz E: 2 articles (06/2008 - 05/2007)

Related Diseases

1.	Infections 07/01/2011 - "In the pulmonary infection model, modithromycin showed greater or comparable efficacy against erm(B)-carrying S. " 04/01/2011 - "Modithromycin should be a useful agent for treatment of pulmonary infections caused by this pathogen." 06/01/2008 - "The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection."
2.	Body Weight (Weight, Body) 04/01/2011 - "Once-daily administration of modithromycin at a dose of 10 mg/kg of body weight for 5 days led to a significant decrease of intrapulmonary viable L. " 05/01/2007 - "Mice infected with macrolide-susceptible MAC strain 101 were given 100 mg of EDP-420/kg of body weight daily for 4 weeks and showed a significant reduction in the number of bacteria in both liver and spleen which was greater than the reduction observed with clarithromycin treatment at the same dose (P < 0.05). "
3.	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 03/01/2008 - "To test the efficacy of EDP-420, a new ketolide, in experimental pneumococcal meningitis and to determine its penetration into the CSF. " 03/01/2008 - "EDP-420 is an efficacious alternative treatment in pneumococcal meningitis, especially when resistant strains are suspected."
4.	Respiratory Tract Infections (Respiratory Tract Infection) 05/01/2009 - "Based on its human pharmacokinetic profiles, taken together with its in vitro/in vivo activity against common respiratory pathogens, EDP-420 warrants efficacy trials for the treatment of respiratory tract infections." 02/01/2010 - "S-013420 (EDP-420) is a novel bicyclolide (bridged bicyclic macrolide) antibacterial currently under development for the treatment of respiratory tract infections. " 08/01/2009 - "EDP-420 (also known as EP-013420, or S-013420) is a first-in-class bridged bicyclolide currently in clinical development for the treatment of respiratory tract infections (RTI) and has previously shown favorable pharmacokinetic (PK) and safety profiles after the administration of single oral doses of a suspension to healthy volunteers. " 05/01/2009 - "EDP-420 (EP-013420, S-013420) is a first-in-class bicyclolide (bridged bicyclic macrolide) currently in clinical development for the treatment of respiratory tract infections. "
5.	Pneumonia (Pneumonitis) 06/01/2014 - "The pharmacodynamic profile of modithromycin (EDP-420, EP-013420, S-013420), a novel bicyclolide, was evaluated in a neutropenic pneumococcal murine pneumonia model. " 06/01/2014 - "Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model."

Related Drugs and Biologics

1.	Clarithromycin (Biaxin)
2.	Macrolides
3.	Quinolones
4.	Vancomycin
5.	Suspensions
6.	Penicillins (Penicillin)
7.	Ceftriaxone (Ceftriaxon)